Wednesday, April 07, 2021 4:28:30 PM
Although her NWBO job title NWBO may suggest otherwise, I dont believe for a second she is hired to accompany and manage the registry of DCVAX with the Canadian RA. There is zero indication from her CV that suggests she is capable/has any interest of doing so. Besides how many hours per day one could spend doing that? The Canadian RA will follow the FDA in approval. Thus if its the consensus of the board is that the Canadian RA needs a full-time NWBO employee to get approval in CA then thats is very bad news for US approval, if you know what I mean.
I sincerely believe they hired her to manage an investment of a large big pharma in NWBO and or the selling of DCVAX royalties. Or perhaps even the acquisition of NWBO altogether. Then the Q remains why the job title program director? Well given the stock price sensitivity of her real job, they could hardly call it "manager of investment strategist" or "head sales DCVAX royalties" or something like that.
I sincerely believe they hired her to manage an investment of a large big pharma in NWBO and or the selling of DCVAX royalties. Or perhaps even the acquisition of NWBO altogether. Then the Q remains why the job title program director? Well given the stock price sensitivity of her real job, they could hardly call it "manager of investment strategist" or "head sales DCVAX royalties" or something like that.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
